Shares in Novo rose almost 4% after the company revised its outlook and off the back of the sales from Ozempic, which were above forecasts. The company expects 2019 sales growth of 2-5% and ...

After a regulatory hiccup earlier this month, Novo Nordisk’s heart failure ambitions for its obesity star Wegovy (semaglutide) are starting to get back on track. Novo’s semaglutide cut the ...

A trial exploring the use of a higher dose of Novo Nordisk's GLP-1 agonist semaglutide has shown that patients with obesity who were taking the drug were able to shed more than a fifth of their ...

Novo Nordisk said the safety risks associated with compounded semaglutide are “significant”. The company outlaid key differences in formulations – such as pharmacies using synthetic ...

Those results were sufficient for the trial to meet its primary endpoints, Novo Nordisk said in a Friday release. Digging deeper into the data, 37% of patients treated with semaglutide achieved ...

A new study is adding to evidence that GLP-1 drugs such as Novo Nordisk's (NVO) semaglutide and Eli Lilly's (LLY) tirzepatide could also be effective in tackling Alzheimer's disease. The study was ...

Novo Nordisk said the data on 10 deaths and more than 100 hospitalizations came from the US Food and Drug Administration’s adverse event reporting database for semaglutide; the FDA warns that ...

The FDA has since said it is reviewing its decision. Last week, Novo Nordisk (NVO) asked the FDA to have semaglutide placed on the Demonstrable Difficulties for Compounding List, arguing that ...